References
- Patterson C. The state of the art of dementia research: new frontiers. London: Alzheimer’s Disease International; 2018.
- Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dementia J Alzheimers Assoc. 2018;14(3):367–429. doi: 10.1016/j.jalz.2018.02.001.
- Liyanage SI, Santos C, Weaver DF. The hidden variables problem in Alzheimer’s disease clinical trial design. Alzheimers Dementia Transl Res Clin Interventions. 2018;4:628–635. [cited 2018 Dec 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30519628
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1759558
- Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3 Pt 1):631–639. [cited 2018 Dec 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1549228
- Le Page A, Dupuis G, Frost EH, Larbi A, Pawelec G, Witkowski JM, Fulop T. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Exp Gerontol. 2018;107(July 2017):59–66. [cited 2018 Dec 20]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0531556517305417
- Birge SJ, Morrow-Howell N, Proctor EK. Hip Fracture. Clin Geriatr Med. 1994; 10(4):589–609. doi:10.1016/S0749-0690(18)30318-5.
- Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging. Milan, Italy). 1996;8(3):189–196. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8862194
- Melton LJ, Beard CM, Kokmen E, Atkinson EJ, O’Fallon WM. Fracture Risk in Patients with Alzheimer’s Disease. J Am Geriatr Soc. 1994; 42(6):614–619. doi:10.1111/j.1532-5415.1994.tb06859.x.
- Weller I, Schatzker J. Hip fractures and Alzheimer’s disease in elderly institutionalized Canadians. Ann Epidemiol. 2004; 14(5):319–324. doi:10.1016/j.annepidem.2003.08.005.
- Zhou R, Zhou H, Rui L, Xu J. Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer’s disease. Curr Alzheimer Res. 2014;11(7):706–713. [cited 2018 Jan 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25115539
- Weller. The relation between hip fracture and alzheimer’s disease in the canadian national population health survey health institutions data, 1994-1995. A cross-sectional study. Ann Epidemiol. 2000;10(7):461. [cited 2018 Dec 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11018377
- Amouzougan A, Lafaie L, Marotte H, Dẻnariẻ D, Collet P, Pallot-Prades B, Thomas T. High prevalence of dementia in women with osteoporosis. Joint Bone Spine. 2016 Sep 30. [cited 2017 Mar 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27697401
- Liu D, Zhou H, Tao Y, Tan J, Chen L, Huang H, Chen Y, Li Y, Zhou R. Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: the Chongqing Aging Study. Curr Alzheimer Res. 2016; 13(10):1165–1172. doi:10.2174/15672050113109990149.
- Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–1081. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8790235
- Kua EH, Ho E, Tan HH, Tsoi C, Thng C, Mahendran R. The natural history of dementia. Psychogeriatrics. 2014;14(3):196–201. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25323961
- McMaster M, Kim S, Clare L, Torres SJ, D’Este C, Anstey KJ. Body, Brain, Life for Cognitive Decline (BBL-CD): protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairment. Clin Interv Aging. 2018;13:2397–2406. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30538436
- Serrano-Aguilar PG, Lopez-Bastida J, Yanes-Lopez V. Impact on Health-Related Quality of Life and Perceived Burden of Informal Caregivers of Individuals with Alzheimer’s Disease. Neuroepidemiology. 2006];27(3):136–142. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16974108
- Morris JC, Rubin EH, Morris EJ, Mandel SA. Senile Dementia of the Alzheimer’s Type: an Important Risk Factor for Serious Falls. J Gerontol. 1987;42(4):412–417. [cited 2018 Oct 23]. Available from: https://academic.oup.com/geronj/article-lookup/doi/10.1093/geronj/42.4.412
- Tan ZS, Seshadri S, Beiser A, Zhang Y, Felson D, Hannan MT, Au R, Wolf PA, Kiel DP. Bone mineral density and the risk of alzheimer disease. Arch Neurol. 2005;62(1):107–111. [cited 2016 Mar 31]. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-12144277271&partnerID=40&md5=4224ccacf6e5e2e3cb60a2cf4fb89c80
- Zhou R, Deng J, Zhang M, Zhou H-D-D, Wang Y-J-J. Association between bone mineral density and the risk of Alzheimer’s disease. J Alzheimers Dis. 2011;24(1):101–108. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21187587
- Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: results From the Women’s Health Initiative Randomized Trial. J Bone Miner Res. 2006;21(6):817–828. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16753012
- Epstein S, Inzerillo AM, Caminis J, Zaidi M. Disorders Associated With Acute Rapid and Severe Bone Loss. J Bone Miner Res. 2003;18(12):2083–2094. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14672343
- Oppl B, Michitsch G, Misof B, Kudlacek S, Donis J, Klaushofer K, Zwerina J, Zwettler E. Low bone mineral density and fragility fractures in permanent vegetative state patients. J Bone Miner Res. 2014;29(5):1096–1100. [cited 2018 Dec 18]. Available from: http://www.wiley.com/
- Villareal DT, Civettelli R, Chines A, Avioli LV. Subclinical Vitamin D Deficiency in Postmenopausal Women with Low Vertebral Bone Mass*. JClin Endocrinol Metab. 1991;72(3):628–634. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1997517
- Boskey AL, Imbert L. Bone quality changes associated with aging and disease: a review. Ann N Y Acad Sci. 2017;1410(1):93–106. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29265417
- Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996;18(5):397–403. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8739896
- Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013];28(1):2–17. [cited 2018 Oct 19]. Available from: http://www.wiley.com/
- Singh M, Arora S, Kaur A, Ghildiyal S, Kumar R. Patterns of age- and sex-related variations in bone mineral density of lumbar spine and total femur: A retrospective diagnostic laboratory-based study. J Midlife Health. 2018;9(3):155. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30294189
- Moreno-Jiménez EP, Flor-García M, Terreros-Roncal J, Rábano A, Cafini F, Pallas-Bazarra N, Ávila J, Llorens-Martín M. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat Med. 2019;25(4):554–560. [cited 2019 Apr 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30911133
- Davalos AR, Kawahara M, Malhotra GK, Schaum N, Huang J, Ved U, Beausejour CM, Coppe J-P, Rodier F, Campisi J. p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol. 2013;201(4):613–629. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23649808
- Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez P-Y, Campisi J. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor Downward J, editor. PLoS Biol. 2008;6(12):e301. [cited 2019 Apr 8]. doi:10.1371/journal.pbio.0060301.
- Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dementia Transl Res Clin Interventions. 2018;4: 575–590. [accessed 2019 Apr 8]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352873718300490
- Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer’s Disease. Brain Pathol. 2009;19(3):392–398. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18637012
- Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski JQ, Sell C, Torres C. Astrocyte senescence as a component of Alzheimer’s disease. Jc Z, editor. PLoS One. 2012;7(9): e45069. [cited 2019 Apr 4]. Available from: https://dx.plos.org/10.1371/journal.pone.0045069
- Flanary BE, Streit WJ. Effects of axotomy on telomere length, telomerase activity, and protein in activated microglia. J Neurosci Res. 2005;82(2):160–171. [cited 2019 Apr 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16175576
- Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. Evidence That Aging And Amyloid Promote Microglial Cell Senescence. Rejuvenation Res. 2007;10(1):61–74. [cited 2019 Apr 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17378753
- Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072–1079. [cited 2019 Apr 8] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28825716
- Farr J, Rowsey J, Eckhardt B, Thicke B, Fraser D, Tchkonia T, Kirkland, Monroe JD, Khosla S. Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: evidence in Young Adult Mice and Older Humans. J Bone Miner Res. 2019 Mar 26;jbmr.3729. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30913313
- Pei -J-J, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer’s disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis JAD. 2001;3(1):41–48. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12214071
- Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R. Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993;629(2):245–252. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7509248.
- Lord J, Cruchaga C. The epigenetic landscape of Alzheimer’s disease. Nat Neurosci. 2014 [accessed 2019 Apr 8];17(9):1138–1140. Available from: http://www.nature.com/articles/nn.3792
- Sohrabi HR, Bates KA, Weinborn M, Bucks RS, Rainey-Smith SR, Rodrigues MA, Bird SM, Brown BM, Beilby J, Howard M. Bone mineral density, adiposity, and cognitive functions. Front Aging Neurosci. 2015;7:(FEB):1–10.
- Kunkle BW, Vardarajan BN, Naj AC, Whitehead PL, Rolati S, Slifer S, Carney RM, Cuccaro ML, Vance JM, Gilbert JR. Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport. JAMA Neurol. 2017;74(9):1113. doi:10.1001/jamaneurol.2017.1518.
- Dorey E, Chang N, Liu QY, Yang Z, Zhang W. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease. Neurosci Bull. 2014; 30(2):317–330. doi:10.1007/s12264-013-1422-z.
- Xia WF, Jung JU, Shun C, Xiong S, Xiong L, Shi XM, Mei L, Xiong WC. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013; 28(10):2122–2135. doi:10.1002/jbmr.1954.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (New York, N.Y.). 1993;261(5123)921–923. [cited 2018 Jan]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8346443
- Parhami F, Mody N, Gharavi N, Ballard AJ, Tintut Y, Demer LL. Role of the Cholesterol Biosynthetic Pathway in Osteoblastic Differentiation of Marrow Stromal Cells. J Bone Miner Res. 2002; 17(11):1997–2003. doi:10.1359/jbmr.2002.17.11.1997.
- Johnston JM, Cauley JA, Ganguli M. APOE 4 and hip fracture risk in a community-based study of older adults. J Am Geriatr Soc. 1999;47(11):1342–1345. doi:10.1111/j.1532-5415.1999.tb07436.x.
- Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H. TREM2 and -Catenin Regulate Bone Homeostasis by Controlling the Rate of Osteoclastogenesis. J Immunol. 2012;188(6):2612–2621. doi:10.4049/jimmunol.1102836.
- Zheng H, Jia L, Liu -C-C, Rong Z, Zhong L, Yang L, Chen X-F, Fryer JD, Wang X, Zhang Y. TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway. J Neurosci. 2017];37(7):1772–1784. [cited 2018 Jan 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28077724
- Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–127. [cited 2016 Apr 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23150934
- Marsell R, Sisask G, Nilsson Y, Sundgren-Andersson AK, Andersson U, Larsson S, Nilsson O, Ljunggren O, Jonsson KB. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone. 2012;50(3):619–627. [cited 2018 Jan 19]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S8756328211013469
- Paloneva J, Kestilä M, Wu J, Salminen A, Böhling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25(3): 357–361. [cited 2018 Jan 19]. Available from: http://www.nature.com/doifinder/10.1038/77153
- O’Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J. Postmenopausal Hormone Therapy Is Not Associated With Risk of All-Cause Dementia and Alzheimer’s Disease. Epidemiol Rev. 2014;36(1):83–103. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24042430
- Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007; 27(48):13357–13365. doi:10.1523/JNEUROSCI.2718-07.2007.
- Zhao Y, Shen L, Ji HF. Alzheimer’s disease and risk of hip fracture: A meta-analysis study. Sci World J. 2012;2012(CXD).doi:10.1100/2012/872173
- Chang KH, Chung CJ, Lin CL, Sung FC, Wu TN, Kao CH. Increased risk of dementia in patients with osteoporosis: A population-based retrospective cohort analysis. Age. 2014; 36(2):967–975. doi:10.1007/s11357-013-9608-x.
- Tiihonen M, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S. Incidence and duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease. J Alzheimers Dis. 2016; 52(1):127–132. doi:10.3233/JAD-151181.
- Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos. 2016;11(1):26. [cited 2018 Jan 19] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27475642
- Ogama N, Sakurai T, Kawashima S, Tanikawa T, Tokuda H, Satake S, Miura H, Shimizu A, Kokubo M, Niida S. Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. J Clin Med. 2019;8(3):319. [cited 2019 Apr 4]. Available from: https://www.mdpi.com/2077-0383/8/3/319
- Ogawa Y, Kaneko Y, Sato T, Shimizu S, Kanetaka H, Hanyu S. Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease. Front Neurol. 2018;9:710. [cited 2019 Apr 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30210435
- Melton LJ, Beard CM, Kokmen E, Atkinson EJ, O’Fallon WM. Fracture risk in patients with Alzheimer’s disease. J Am Geriatr Soc. 1994;42(6):614–619. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8201146
- Tamimi I, Ojea T, Sanchez-Siles JM, Rojas F, Martin I, Gormaz I, Perez A, Dawid-Milner MS, Mendez L, Tamimi F. Acetylcholinesterase inhibitors and the risk of hip fracture in alzheimer’s disease patients: A case-control study. J Bone Miner Res. 2012;27(7):1518–1527. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22467182
- Olazarán J, Hernández-Tamames JA, Molina E, García-Polo P, Dobato JL, Álvarez-Linera J, Martínez-Martín P. AD Research Unit Investigators. Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer’s Disease. J Alzheimers Dis. 2012;33(2): 495–505. [cited 2018 Dec 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23011219
- Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and brain atrophy in early Alzheimer’s disease. J Alzheimers Dis JAD. 2009;18(4):777–785. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19661621
- Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005;65(6):892–897. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16186530
- Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71(14):1057–1064. [cited 2019 Apr 4] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18367704
- Grinberg LT, Rüb U, Ferretti REL, Nitrini R, Farfel JM, Polichiso L, Gierga K, Jacob-Filho W, Heinsen H. Brazilian Brain Bank Study Group. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset? Neuropathol Appl Neurobiol. 2009;35(4): 406–416. [accessed 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19508444
- Sen B, Styner M, Xie Z, Case N, Rubin CT, Rubin J. Mechanical Loading Regulates NFATc1 and β-Catenin Signaling through a GSK3β Control Node. J Biol Chem. 2009;55(4):1605–1619. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19840939
- Dengler-Crish CM, Smith MA, Wilson GN. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer’s Disease Grinberg L, editor. J Alzheimers Dis. 2016;55(4):1605–1619. [cited 2019 Jan 17]. Available from: http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-160658
- Schwartz AV, Kelsey JL, Sidney S, Grisso JA. Characteristics of Falls and Risk of Hip Fracture in Elderly Men. Osteoporosis Int. 1998;8(3):240–246. [cited 2018 Dec 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9797908
- Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Da GZ, Li YZ, Guo BL. Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine. 2011; 18(2–3):205–213. doi:10.1016/j.phymed.2010.05.011.
- Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic Mice Overexpressing Amyloid Precursor Protein Exhibit Early Metabolic Deficits and a Pathologically Low Leptin State Associated with Hypothalamic Dysfunction in Arcuate Neuropeptide Y Neurons. J Neurosci. 2014;34(27):9096–9106. [cited 2016 Mar 31]. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.0872-14.2014
- Yadav VK, Oury F, Suda N, Liu Z-W, Gao X-B, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976–989. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19737523
- Ramos-Rodriguez JJ, Molina-Gil S, Rey-Brea R, Berrocoso E, Garcia-Alloza M. Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice. PLoS One. 2013;8(11):e79947. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24278223
- Aletrino MA, Vogels OJ, Van Domburg PH, Ten Donkelaar HJ. Cell loss in the nucleus raphes dorsalis in Alzheimer’s disease. Neurobiol Aging. 1992;13(4):461–468. [cited 2016 Mar 31] Available from: http://www.ncbi.nlm.nih.gov/pubmed/1508296
- Luckhaus C, Mahabadi B, Grass-Kapanke B, Jänner M, Willenberg H, Jäger M, Supprian T, Fehsel K. Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer’s disease. J Neural Transm. 2009; 116(7):905–911. doi:10.1007/s00702-009-0241-x.
- Rüb U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. The evolution of Alzheimer’s disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol. 2000; 26(6):553–567. doi:10.1046/j.0305-1846.2000.00291.x.
- Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207. [cited 2016Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10660043
- Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–520. [cited 2018 Oct 10]. Available from: http://www.nature.com/articles/nature03398
- Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33):25103–25108. [cited 2018 Dec 20]]. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.R109.041087
- Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, De Cabo R, Jilka RL, Weinstein RS, O’Brien CA, Manolagas SC. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Inves. 2013;123(8):3409–3419. doi:10.1172/JCI68049.
- Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013; 9(12):699–712. doi:10.1038/nrendo.2013.179.
- Shi Y, Oury F, Yadav VK, Wess J, Liu XS, Guo XE, Murshed M, Karsenty G. Signaling through the M3 Muscarinic Receptor Favors Bone Mass Accrual by Decreasing Sympathetic Activity. Cell Metab. 2010; 11(3):231–238. doi:10.1016/j.cmet.2010.01.005.
- Elefteriou F, Campbell P, Ma Y. Control of Bone Remodeling by the Peripheral Sympathetic Nervous System. Calcif Tissue Int. 2014;94(1):140–151. [accessed 2017 Feb 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23765388
- Yadav VK, Karsenty G. Leptin-dependent co-regulation of bone and energy metabolism. Aging. 2009; 1(11):954–956. doi:10.18632/aging.100100.
- Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–317. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12419242
- Oury F, Yadav VK, Wang Y, Zhou B, Liu XS, Guo XE, Tecott LH, Schutz G, Means AR, Karsenty G. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev. 2010;24(20):2330–2342. [cited 2018 Oct 10]. Available from: http://genesdev.cshlp.org/cgi/doi/10.1101/gad.1977210
- Duncan CP, Shim SS. J. Edouard Samson Address: the autonomic nerve supply of bone. An experimental study of the intraosseous adrenergic nervi vasorum in the rabbit. J Bone Joint Surg Br. 1977;59(3):323–330. [cited 2018Sep 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19482
- Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CPL-H, Francis PT, Lasheras B, Ramirez MJ. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–449. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15707619
- Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008;473(2):231–236. [cited 2017 Feb 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18410742
- Bataille C, Mauprivez C, Haÿ E, Baroukh B, Brun A, Chaussain C, Marie PJ, Saffar J-L CM. Different sympathetic pathways control the metabolism of distinct bone envelopes. Bone. 2012; 50(5):1162–1172. doi:10.1016/j.bone.2012.01.023.
- Bajayo A, Bar A, Denes A, Bachar M, Kram V, Attar-Namdar M, Zallone A, Kovacs KJ, Yirmiya R, Bab I. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc Natl Acad Sci. 2012; 109(38):15455–15460. doi:10.1073/pnas.1206061109.
- Kanno K, Shima S, Ishida Y, Yamanouchi K. Ipsilateral and contralateral serotonergic projections from dorsal and median raphe nuclei to the forebrain in rats: immunofluorescence quantitative analysis. Neurosci Res. 2008;61(2):207–218. [cited 2016Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18423675
- Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995 [[accessed 2016 Sep 27];16(3):271–8; discussion 278–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7566337
- Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):313–322. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20164583
- He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, Dengler C. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 2017;24(1):29–38. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29200205
- Nakanishi A, Kaneko N, Takeda H, Sawasaki T, Morikawa S, Zhou W, Kurata M, Yamamoto T, Akbar SMF, Zako T. Amyloid β directly interacts with NLRP3 to initiate inflammasome activation: identification of an intrinsic NLRP3 ligand in a cell-free system. Inflamm Regen. 2018;38(1): 27. [cited 2018 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30459926
- Aamodt EJ, Williams RC. Microtubule-associated proteins connect microtubules and neurofilaments in vitro. Biochemistry. 1984;23(25):6023–6031. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6543144
- Weisshaar B, Matus A. Microtubule-associated protein 2 and the organization of cellular microtubules. J Neurocytol. 1993;22(9):727–734. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8270957
- Cui S, Xiong F, Hong Y, Jung J-U, Li X-S, Liu J-Z, Yan R, Mei L, Feng X, Xiong W-C. APPswe/Amyloid Beta regulation of osteoclast activation and RAGE expression in an age dependent manner. J Bone Miner Res. 2011; 26(5):1084–1098. doi:10.1038/nphoton.2014.166.Through-skull.
- Xia W-F, Jung J-U, Shun C, Xiong S, Xiong L, Shi X-M, Mei L, Xiong W-C. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013;28(10):2122–2135. Mar 31 [cited 2016]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23649480
- Peng Y, Liu J, Tang Y, Liu J, Han T, Han S, Li H, Hou C, Liu J, Long J. High-Fat-Diet-Induced Weight Gain Ameliorates Bone Loss without Exacerbating AβPP Processing and Cognition in Female APP/PS1 Mice. Front Cell Neurosci. 2014;8((August):225).doi:10.3389/fncel.2014.00225
- Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86(3):582–590. [cited 2016 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12859672
- Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29(34):10741–10749. [cited 2016 Sep 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19710325
- Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins. Neuron. 1997;19(4):939–945. [cited 2018 Jun 5]. Available from: https://www.sciencedirect.com/science/article/pii/S0896627300809745
- Zhao L, Liu S, Wang Y, Zhang Q, Zhao W, Wang Z, Yin M. Effects of curculigoside on memory impairment and bone loss via anti-oxidative character in APP/PS1 mutated transgenic mice. PLoS One. 2015; 10(7):1–13. doi:10.1371/journal.pone.0133289.
- Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19(4):939–945. doi:10.1016/S0896-6273(00)80974-5.
- Xia W-F, Jung J-U, Shun C, Xiong S, Xiong L, Shi X-M, Mei L, Xiong W-C. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013];28(10):2122–2135. [cited 2019 Jan 17]. Available from: http://doi.wiley.com/10.1002/jbmr.1954
- Li S, Liu B, Zhang L, Rong L. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. Bone. 2014;61:164–175. DOI:10.1016/j.bone.2014.01.010.
- Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116(5):1202–1209. [cited 2018 Jan 19]]. Available from: http://www.jci.org/cgi/doi/10.1172/JCI28551
- Oliva CA, Vargas JY, Inestrosa NC. Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci. 2013;7:224. [cited 2018 Jan 19] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24348327
- Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature. 2002;417(6889): 664–667. [cited 2018 Jan 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12050670
- De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A. Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer’s disease. Proc Natl Acad Sci. 2007;104(22):9434–9439. doi:10.1073/pnas.0603523104.
- Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol. 2014;6(1):64–74. [cited 2018 Jan 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24549157. doi:10.1093/jmcb/mjt051.
- Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G, Copani A, Nicoletti F, Terstappen GC. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis. 2006];24(2):254–265. [cited 2018 Jan 19]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0969996106001550
- Dengler-Crish CM, Ball HC, Lin L, Novak KM, Cooper LN. Evidence of Wnt/β-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer’s disease. Neurobiol Aging. 2018];67:148–158. [cited 2018 Jun 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29660685
- Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468. [cited 2019 Jan 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22237023
- Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, Lu P, Sartini L, Di Comite M, Mori G. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci. 2015;112(39):12157–12162. doi:10.1073/pnas.1516622112.
- Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD, Kim E, Rompala A, Oram MK, Asselin C. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science. 2018;361:6406.
- M V L, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, Gonçalves RA, Clarke JR, Beckman D, Staniszewski A. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med. 2019;25(1):165–175. [cited 2019 Jan 17]. Available from: http://www.nature.com/articles/s41591-018-0275-4
- Xiong XQ, Chen D, Sun HJ, Ding L, Wang JJ, Chen Q, Li YH, Zhou YB, Han Y, Zhang F. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta Mol Basis Dis. 2015;1852(9):1867–1875. doi:10.1016/j.bbadis.2015.06.017.
- Zhang D, Xie T, Leung PS. Irisin Ameliorates Glucolipotoxicity-Associated β-Cell Dysfunction and Apoptosis via AMPK Signaling and Anti-Inflammatory Actions. Cell Physiol Biochem. 2018;51(2):924–937. doi:10.1159/000495395.
- Schumacher MA, Chinnam N, Ohashi T, Shah RS, Erickson HP. The Structure of Irisin Reveals a Novel Intersubunit β-Sheet Fibronectin Type III (FNIII) Dimer. J Biol Chem. 2013;288(47):33738–33744. [cited 2019 Jan 17]. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.M113.516641
- Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Cakmak T, Albayrak S, Gungor S, Colakoglu N, Ozercan IH. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014;61:130–136. DOI:10.1016/j.peptides.2014.09.014.
- Albayrak S, Atci IB, Kalayci M, Yilmaz M, Kuloglu T, Aydin S, Kom M, Ayden O, Aydin S. Effect of carnosine, methylprednisolone and their combined application on irisin levels in the plasma and brain of rats with acute spinal cord injury. Neuropeptides. 2015;52:47–54. DOI:10.1016/j.npep.2015.06.004.
- Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, Zhou C, Chou J, Parkman V-JA, Novick SJ. Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors. Cell. 2018];175(7):1756–1768.e17. [cited 2019 Jan 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30550785
- Zhang J, Valverde P, Zhu X, Murray D, Wu Y, Yu L, Jiang H, Dard MM, Huang J, Xu Z. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res. 2017;5: 16056. [cited 2019 Jan 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28944087
- Colaianni G, Mongelli T, Cuscito C, Pignataro P, Lippo L, Spiro G, Notarnicola A, Severi I, Passeri G, Mori G. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci Rep. 2017;7(1):2811. [cited 2019 Jan 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28588307
- Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, Filippaios A, Mantzoros CS. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporosis Int. a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014;25(5):1633–1642. [cited 2019 Jan 3]. Available from: http://link.springer.com/10.1007/s00198-014-2673-x
- Wu L-F, Zhu D-C, Tang C-H, Ge B, Shi J, Wang B-H, Lu Y-H, He P, Wang W-Y, Lu S-Q. Association of Plasma Irisin with Bone Mineral Density in a Large Chinese Population Using an Extreme Sampling Design. Calcif Tissue Int. 2018;103(3):246–251. [cited 2019 Jan 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29582132
- Bourhis E, Wang W, Tam C, Hwang J, Zhang Y, Spittler D, Huang OW, Gong Y, Estevez A, Zilberleyb I. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure. (London, England : 1993). 2011;19(10):1433–1442. [cited 2018 Jan 19]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0969212611002474
- Pflanz D, Birkhold AI, Albiol L, Thiele T, Julien C, Seliger A, Thomson E, Kramer I, Kneissel M, Duda GN. Sost deficiency led to a greater cortical bone formation response to mechanical loading and altered gene expression. Sci Rep. 2017;7(1):9435. [cited 2019 Apr 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28842678
- Yu P-A, Hsu W-H, Hsu W-B, Kuo L-T, Lin Z-R, Shen W-J, Hsu R-W-W. The effects of high impact exercise intervention on bone mineral density, physical fitness, and quality of life in postmenopausal women with osteopenia. Medicine. 2019;98(11):e14898. [cited 2019 Apr 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30882707
- Eatemadololama A, Karimi MT, Rahnama N, Rasolzadegan MH. Resistance exercise training restores bone mineral density in renal transplant recipients. Clin Cases Miner Bone Metab. 2017;14(2):157–160. [cited 2019 Apr 5]. Available from: https://www.ccmbm.com/common/php/portiere.php?ID=3a1df55f20ff25b33a6fb0d2d1c1c083
- Kim C, Park D. The effect of restriction of dietary calcium on trabecular and cortical bone mineral density in the rats. J Exercise Nutr Biochem. 2013; 17(4):123–131. doi:10.5717/jenb.2013.17.4.123.
- Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, Lin JD, Greenberg ME, Spiegelman BM. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. 2014;18(5):617–632. doi:10.1016/j.cmet.2013.09.008.Exercise.
- Siteneski A, Cunha MP, Lieberknecht V, Pazini FL, Gruhn K, Brocardo PS, Rodrigues ALS. Central irisin administration affords antidepressant-like effect and modulates neuroplasticity-related genes in the hippocampus and prefrontal cortex of mice. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(February):294–303. doi:10.1016/j.pnpbp.2018.03.004.
- Kobilo T, Yuan C, van Praag H. Endurance factors improve hippocampal neurogenesis and spatial memory in mice. Learn Memory. 2011;18(2):103–107. [cited 2019 Apr 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21245211
- Asadi Y, Gorjipour F, Behrouzifar S, Vakili A. Irisin Peptide Protects Brain Against Ischemic Injury Through Reducing Apoptosis and Enhancing BDNF in a Rodent Model of Stroke. Neurochem Res. 2018; 43(8):1549–1560. doi:10.1007/s11064-018-2569-9.
- Noda Y, Kuzuya A, Tanigawa K, Araki M, Kawai R, Ma B, Sasakura Y, Maesako M, Tashiro Y, Miyamoto M. Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease. Mol Brain. 2018;11:61.
- Moreno M, Moreno-Navarrete JM, Serrano M, Ortega F, Delgado E, Sanchez-Ragnarsson C, Valdés S, Botas P, Ricart W, Fernández-Real JM. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015; 10(4):1–11. doi:10.1371/journal.pone.0124100.
- Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(4):1485–1493. doi:10.1210/jc.2014-2544.
- Looker AC, Borrud LG, Dawson-Hughes B, Shepherd JA, Wright NC. Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: united States, 2005-2008. NCHS Data Brief. 2012;(93):1–8. [cited 2016 Mar 31] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22617299
- Salcedo-Tello P, Hernández-Ortega K, Arias C. Susceptibility to GSK3β-induced tau phosphorylation differs between the young and aged hippocampus after Wnt signaling inhibition. J Alzheimers Dis JAD. 2014;39(4):775–785. [cited 2018 Jan 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24270208
- Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid β-mediated synaptic loss. J Neurosci. 2012;32(10):3492–3498. [cited 2018 Jan 19]. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4562-11.2012
- Parr C, Mirzaei N, Christian M, Sastre M. Activation of the Wnt/β-catenin pathway represses the transcription of the β-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. Faseb J. 2015;29(2):623–635. [cited 2018 Jan 19]. Available from: http://www.fasebj.org/doi/10.1096/fj.14-253211
- Pérez-Campo FM, Santurtún A, García-Ibarbia C, Pascual MA, Valero C, Garcés C, Sañudo C, Zarrabeitia MT, Riancho JA. Osterix and RUNX2 are transcriptional regulators of sclerostin in human bone. Calcif Tissue Int. 2016;99(3):302–309. [cited 2018 Jan 19]. Available from: http://link.springer.com/10.1007/s00223-016-0144-4